CN105367658B - Human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG and application thereof - Google Patents
Human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG and application thereof Download PDFInfo
- Publication number
- CN105367658B CN105367658B CN201510870684.5A CN201510870684A CN105367658B CN 105367658 B CN105367658 B CN 105367658B CN 201510870684 A CN201510870684 A CN 201510870684A CN 105367658 B CN105367658 B CN 105367658B
- Authority
- CN
- China
- Prior art keywords
- lectin
- antibody
- sialic acid
- ser
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Human anti-sialic acid binds antibody IgG of immunoglobulin-like lectin-9 and its application, the amino acid sequence of heavy chain variable region is shown as SEQ ID NO. 2; the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 9. The human antibody can be specifically combined with sialic acid binding immunoglobulin-like lectin-9; in vitro cell experiment results prove that the humanized anti-sialic acid binding immunoglobulin-like lectin-9 antibody can effectively induce apoptosis of sialic acid binding immunoglobulin-like lectin-9 positive cells and inhibit secretion of cytokines, so that the monoclonal antibody can be applied to clinical treatment and prevention of relevant diseases such as severe asthma, chronic obstructive pulmonary disease, autoimmune diseases, tumors and the like.
Description
Technical Field
The invention belongs to the technical field of monoclonal antibody medicines, and relates to a full-molecular human monoclonal antibody for resisting sialic acid combined with immunoglobulin-like lectin-9 (the surface biological acid-binding immunoglobulin-like lectin-9, Siglec-9), a coded DNA molecule thereof, and application of the full-molecular human monoclonal antibody in preparation of medicines for treating diseases such as severe asthma, chronic obstructive pulmonary disease, autoimmune diseases and tumors.
Background
Sialic acid-binding immunoglobulin-like lectins (siglecs) are important members of the immunoglobulin superfamily, and can mediate cell-cell or pathogen interactions by recognizing sialic acid-containing sugar chain structures. Recent studies show that the siglec family plays an important role in cell activation, proliferation and apoptosis, plays an important regulatory role in innate immunity and adaptive immunity, and can also participate in the regulation of immune tolerance.
Siglecs are members of the immunoglobulin superfamily, and the common structural feature of the molecules is the ability to bind sialic acid. Sialic acid binds to immunoglobulin-like lectins, is expressed on the surface of immune cells, and mediates inhibitory signals. Similar to other families of inhibitory immunoreceptors, such as killer immunoglobulin-like receptors and leukocyte immunoprotein-like receptors, siglecs are transmembrane molecules that contain immunoreceptor tyrosine inhibitory motifs, ITIMs, in the cytoplasmic tail, and immunoglobulin superfamily regions in the extracellular space. In contrast to other immunoglobulin superfamily, siglecs are characterized by their highly specific ligand sialylated carbohydrates, unlike most other immunoreceptor binding proteins. Humans have found 14 siglecs: sialoadhesin (siglec1CD169), CD22(siglec2), CD33(siglec3) and myelin-associated glycoprotein (MAG siglec4) and more recently CD 33-associated siglec (siglec 5-11). Most of the siglecs family is expressed in hematopoietic cells, except that siglec4 is expressed in neural cells.
Sialic acid binding immunoglobulin-like lectin 9(siglec9) is a type I transmembrane protein, an important member of the immunoglobulin superfamily, consisting mainly of an extracellular N-terminal V-region mediating sialic acid (SIA) recognition and two C-region immunoglobulin-like domains, a transmembrane region and an intracytoplasmic region containing two immunotyrosine inhibitory motifs (ITIMs). The membrane proximal motif ITIM is tyrosine phosphorylated, recruiting inhibitory phosphatases, such as Src homology region 2 including tyrosine phosphatase 1(SHP-1), SHP-2, and SH2 inositol phosphatase (SHIP), thereby mediating downstream tyrosine kinase phosphorylation and transmitting inhibitory or lethal signals intracellularly.
Siglec-9 is highly expressed in neutrophils and monocytes, NK cells, CD4+And CD8+Certain subpopulations of T cells are under-expressed. Siglec-9 can be expressed on the cell membrane surface of the immature granulocyte in the middle and later stages of the differentiation of the bone marrow hematopoietic stem cells, and the Siglec-9 is involved in a plurality of physiological processes such as differentiation, development and death of neutrophils and is an important functional receptor for regulating the innate immunity of the neutrophils. The lung tissue massive eosinophil infiltration with neutrophilia is an important pathophysiological characteristic of severe asthma, and the anti-Siglec-9 antibody substitution treatment combines PCD and PCD, and has potential treatment value in the treatment of severe asthma, chronic obstructive pulmonary disease, autoimmune diseases, tumors and other diseases.
Disclosure of Invention
The technical problem to be solved is as follows: the invention provides human anti-sialic acid antibody IgG combined with immunoglobulin-like lectin-9 and application thereof.
The technical scheme is as follows: human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG, V of said antibodyLThe complementarity determining regions of the strands have the following amino acid sequences of CDRs:
v shown as SEQ ID NO.10L-CDR1；
V shown in SEQ ID NO.11L-CDR2；
V shown as SEQ ID NO.12L-CDR3；
And V of the antibodyHThe complementarity determining regions of the strands have the following amino acid sequences of CDRs:
v shown in SEQ ID NO.3H-CDR1；
V shown in SEQ ID NO.4H-CDR2；
V shown in SEQ ID NO.5H-CDR3。
The human anti-sialic acid binds to IgG antibody of immunoglobulin-like lectin-9, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO. 2; the amino acid sequence of the light chain variable region is shown in SEQ ID NO. 9. And conservative variant obtained by conservative mutation of the sequence through one or more amino acid addition, deletion, substitution and modification.
The human anti-sialic acid binds to IgG antibody of immunoglobulin-like lectin-9, the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO. 7; the amino acid sequence of the light chain constant region is shown in SEQ ID NO. 14. And conservative variant obtained by conservative mutation of the sequence through one or more amino acid addition, deletion, substitution and modification.
The nucleotide sequence of the antibody IgG for coding the human anti-sialic acid combined immunoglobulin-like lectin-9 is shown in SEQ ID NO.1, and the nucleotide sequence of the coding light chain variable region is shown in SEQ ID NO. 8.
The nucleotide sequence of the IgG antibody which codes for the human anti-sialic acid to combine with the immunoglobulin-like agglutinin-9 is shown in SEQ ID NO.6, and the nucleotide sequence of the light chain constant region is shown in SEQ ID NO. 13.
The application of the human anti-sialic acid antibody IgG combined with the immunoglobulin-like lectin-9 in preparing the medicines for preventing or treating severe asthma, chronic obstructive pulmonary disease, autoimmune diseases and/or tumors is disclosed.
A medicine for preventing or treating severe asthma contains human anti-sialic acid antibody IgG conjugated with immunoglobulin-like lectin 9 as effective component.
A medicine for preventing or treating chronic obstructive pulmonary disease contains human anti-sialic acid antibody IgG capable of binding to immunoglobulin-like lectin 9 as effective component.
A medicine for preventing or treating autoimmune diseases contains human anti-sialic acid antibody IgG capable of binding to immunoglobulin-like lectin 9 as effective component.
A medicine for preventing or treating tumor contains human IgG antibody with sialic acid binding immunoglobulin-like lectin-9 as effective component.
Has the advantages that: the invention provides a human monoclonal antibody which has high protection, high specificity and good affinity and is used for resisting sialic acid and combining with immunoglobulin-like lectin-9. The acting energy of the full-molecular humanized antibody can be identified, and the result shows that the humanized antibody can be specifically combined with sialic acid combined immunoglobulin-like lectin-9; in vitro cell experiment results prove that the humanized anti-sialic acid binding immunoglobulin-like lectin-9 antibody can effectively induce apoptosis of sialic acid binding immunoglobulin-like lectin-9 positive cells and inhibit secretion of cytokines, so that the monoclonal antibody can be applied to clinical treatment and prevention of relevant diseases such as severe asthma, chronic obstructive pulmonary disease, autoimmune diseases, tumors and the like.
Drawings
FIG. 1 SDS-PAGE detection of antibody IgG after purification;
FIG. 2 ELISA detection of anti-Siglec-9 antibodies;
FIG. 3 Western blot detection of anti-Siglec-9 antibodies;
FIG. 4 detection of affinity of anti-Siglec-9 antibody binding to antigen;
FIG. 5 anti-Siglec-9 antibody-induced neutrophil apoptosis assay;
FIG. 6 FACS detection of anti-Siglec-9 antibody induced neutrophil ROS.
Detailed Description
The heavy chain variable region and the light chain variable region of the antibody are both human antibodies, and are called full-molecule human antibodies because they are linked to the constant regions of human antibodies.
The invention takes sialic acid combined immunoglobulin-like lectin-9 as a target molecule, and prepares human anti-sialic acid combined immunoglobulin-like lectin-9 antibody IgG on the basis of a phage antibody library technology. The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. It should be understood that the illustrated embodiments are exemplary only, and are not intended to limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit of the invention, and it is intended to cover all such changes and modifications as fall within the scope of the invention.
Example 1
Screening of Fab of human-derived anti-sialic acid-binding immunoglobulin-like lectin-9 antibody
1) Coating the solid phase screening ELISA plate with purified recombinant human sialic acid binding immunoglobulin-like lectin-9 protein, 2 μ g per well, washing, adding blocking solution, washing, adding phage antibody library antibody, and washing to remove unbound phage antibody.
2) Trypsin was added to elute specifically bound phage antibodies and the helper phage VCSM13 was added for superinfection.
3) Repeating the screening steps, and carrying out four rounds of 'adsorption-elution-amplification' enrichment screening.
4) The phage obtained by the last round of screening and proliferation is diluted and then paved on an ampicillin culture plate added with 100 mu g/mL for culture overnight, 80 single colonies are picked up in a cell culture plate and cultured overnight by shaking.
5) After overnight, 5. mu.L of the suspension was transferred from each well of the first plate to the second plate and cultured with shaking.
6) Adding helper phage VCSM13 for superinfection, and shaking for culture; centrifuging, resuspending the precipitate in the culture medium, and culturing overnight with shaking.
7) Centrifuging, taking supernatant, performing ELISA detection, measuring the absorbance of each well at 450nm and 650nm, and calculating the absorbance of each well according to A450 nm-A650 nm. When the P/N value (Positive/Negative) is more than 6, the strain is a Positive monoclonal phage strain.
8) And (3) analyzing the nucleic acid sequence of the positive clone, wherein the nucleic acid sequence of the coding heavy chain variable region is shown as SEQ ID NO.1 in the sequence table, and the nucleic acid sequence of the coding light chain variable region is shown as SEQ ID NO.8 in the sequence table, so that the Fab with the correct gene sequence is obtained.
Preparation of human anti-sialic acid-binding immunoglobulin-like lectin-9 antibody IgG
1) Designing primers of Infusion PCR according to the variable region sequences of the obtained antibodies
The heavy chain PCR amplification primer and the light chain PCR amplification primer of the antibody are designed according to the Infusion PCR principle, the primers need to comprise 15bp bases on an expression vector and at least 15bp bases inserted into a target fragment, and the bases inserted into the target fragment are designed according to the principle of common primer design.
Heavy and light chain PCR amplification primers:
heavy chain amplification primers:
HF:5’-GGTGTCCACTCGCTACAGGTGCAGCTGGTGCAGTCT-3’
HR:5’-GCCCTTGGTGGATGCTGAGGAGACGGTGAC-3’
light chain amplification primers:
L5F:5’-ACAGACGCTCGCTGCTCCTATGAGCTGACTCAGCCACCT-3’
L5R：5’-GTTGGCCTTGGGCTGTAGGACGGTCAGCCT-3’
2) amplification of human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG heavy chain, light chain
And (3) amplifying heavy chain and light chain genes of the full-molecular human antibody by respectively using the prepared human Fab as a template and the related upstream and downstream primers of the heavy chain and the light chain.
①PCR
Reaction system:
reaction conditions are as follows:
and (3) performing ② 2% agarose gel electrophoresis, observing a target band under ultraviolet, cutting the gel and recovering.
③ gel recovery kit purifies the target DNA fragment and elutes with deionized water.
3) Double restriction enzyme IgG expression plasmid
The IgG expression plasmids pFUSE-CHIg-hG1, pFUSE-CLIg-hk (available from Invivogen) contain the base-encoding sequences of the heavy and light chain (Kappa) constant regions of human origin of IgG1, the specific nucleotide sequence encoding the heavy chain constant region being shown in SEQ ID NO.7 and the specific nucleotide sequence encoding the light chain constant region being shown in SEQ ID NO. 14.
① pFUSE-CHIg-hG1 pFUSE-CLIg-hk template vector double enzyme digestion
Reaction system:
reaction conditions are as follows: the cleavage was carried out overnight at 37 ℃.
② 1% agarose gel electrophoresis, ultraviolet cutting gel recovery.
③ gel recovery kit purifies the target DNA fragment and elutes with deionized water.
4) Infusion PCR recombinant expression plasmid
Reaction system:
reaction conditions are as follows: incubate at 50 ℃ for 15 min.
5 mul of reaction solution was taken to transform competent bacteria, spread on the corresponding resistant plates, and the next day clones were picked for sequencing. And cloning and preserving strains with correct sequencing results, carrying out amplification culture, and extracting plasmids.
5) Expression of human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG
① mu.L of pFUSE-CHIg-hG1-H (i.e., 50. mu.g) was put in 1mL of Opti-MEM medium, 250. mu.L of pFUSE-CLIg-hk-L (i.e., 50. mu.g) was put in 1mL of Opti-MEM medium, 200. mu.L of 293Fectin was put in 2.8mL of Opti-MEM medium, and the three mixtures were allowed to stand at room temperature for 5 min.
② mixing the two plasmid mixed solutions evenly, adding 500 μ L Opti-MEM culture Medium, mixing evenly, adding the mixed solution of the transfection reagent 293Fectin directly, mixing evenly, standing for 20min, treating 293F cells, centrifuging 293F cells, resuspending with 293F Expression Medium, counting, calculating cell activity ratio with trypan blue, sucking 100 × 106The cells were placed in a flask and were brought to a volume of 94mL using 293F Expression Medium.
③ 20min was completed and 6mL of the DNA, 293Fectin complex was added to the prepared 293F cells.
④ the cells were cultured in a shaker incubator with 8% CO2Cell supernatants were collected after 6 days at 120rmp, 37 ℃.
6) Purification of IgG antibody of human anti-sialic acid binding immunoglobulin-like lectin-9
The collected cell supernatant was filtered through a 0.22 μm filter while the balance and the eluate were filtered through a membrane. The Protein A was purified using an AKATA purifier according to standard procedures for Protein A purification, loading at 1mL/min, and eluting at 1.5 mL/min. Results IgG antibodies were successfully expressed and purified. The results of SDS-PAGE are shown in FIG. 1.
Functional Activity identification of human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG
1) Enzyme linked immunosorbent assay
Diluting recombinant human sialic acid binding immunoglobulin-like lectin-9 with coating solution (0.1M carbonate buffer, pH9.6) to 2. mu.g/mL coated ELISA 96-well plate, adding 100. mu.L per well, and standing overnight at 4 deg.C; PBST (PBS containing 0.5% Tween20) 5% skimmed milk-wash buffer blocked and incubated at 37 ℃ for 2 h; after 5 PBST washes, 100. mu.L of PA21 antibody (2. mu.g/mL starting concentration, 14 concentration gradient dilutions) was added to each well for 2h at 37 ℃; mixing the raw materials in a ratio of 1: adding 100 mu L/hole of 2000 diluted goat anti-human secondary antibody into the hole, and incubating for 1h at 37 ℃; the peroxidase substrate color developing solution is 100 mu L/hole, the reaction is stopped by 2M sulfuric acid after 10 minutes at room temperature, and the double-wavelength 450nm/690nm is adopted for machine detection and color comparison. As a result, as shown in FIG. 2, human anti-sialic acid-binding IgG immunoglobulin-like lectin 9 antibody bound to Siglec9 protein.
2)Western blot
The neutrophil lysate supernatant was subjected to 10% SDS-PAGE and transferred electrically to a nitrocellulose membrane, which was incubated with 2. mu.g/mL of antibody at room temperature for 1h, and HRP-goat anti-human IgG (Pico, Beijing) and ECL luminescence kit (Pierce, USA) were diluted 1:2000 and exposed to a gel imaging system (Bio-Rad).
The results are shown in FIG. 3: the human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG specifically binds to Siglec-9 protein.
3) Affinity assays
According to the isoelectric point of the antigen and the protocol of Biacore-X100 control soft, the coupling condition is optimized, and sodium acetate is selected as the coupling dilution buffer solution in slope optimization. Antigen samples were diluted to 25. mu.g/mL with this buffer and coupled to CM5 chips. The preset coupling level was 1500 RU. Antigen samples were then diluted with Running buffer at pH7.4 to a range of concentrations of 0uM, 5nM, 10nM 20nM, 40nM, 80 nM. The sample injection time is set to 180s, the dissociation time is set to 10min, and the regeneration buffer is 50mM pH2.2 Gly-HCl. The on-board test was performed according to the protocol of BiacoreX100 control soft. The affinity assay results are shown in FIG. 6, with KD of 7.380X 10-10M。
4) Detection of antibody-induced neutrophil apoptosis
Neutrophils were isolated using Ficoll isolate, pre-treated with GM-CSF for 30 min at 25ng/mL, and Siglec-9mAb at 10. mu.g/mL (B10101) and negative control added, respectively. After 8 hours of action, the cells were stained with Annexin-V and PI and examined by flow cytometry. The result shows that the antibody can induce the apoptosis of the neutrophil granulocytes, and the apoptosis rate reaches 21.15%.
5) ROS detection in cells:
5mL of venous blood is adopted, and the neutrophilic granulocyte is separated from a Ficoll separating medium and divided into three groups: negative control group, GM-CSF group and GM-CSF + siglec-9mAb20 μ g/mL group, each acted for 2 hours. The culture medium was added with 100ng/mL LPS and allowed to act for 1 hour. According to the instructions, add Sigma company ROS probe, 37 degrees were incubated for 30 minutes, ice PBS washed cells three times, flow cytometry detection. The results show that antibody treatment significantly increased ROS levels in neutrophils.
The animal experiment results show that the anti-human sialic acid binding immunoglobulin-like lectin-9 IgG antibody has good immunological activity and can induce apoptosis increase of neutrophils, and the antibody can be used for treating diseases such as severe asthma, chronic obstructive pulmonary disease, autoimmune diseases and tumors.
Sequence listing
<110> Zhu, in
<120> human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG and application thereof
<130>
<160>18
<170>PatentIn version 3.3
<210>1
<211>354
<212>DNA
<213> Artificial sequence
<400>1
gaggtgcagc tggtggagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60
tcctgcaagg cttctggata catcttcacc ggctactata tgcactgggt gcgacaggcc 120
cctggacaag ggcttgagtg gatgggatgg atcaacccta aaagtggtgg cacaaactat 180
gcacagaagt ttcagggcag ggtcaccatg accagggaca cgtccatcag cacagcctat 240
atggagctga gcaggctgag atctgacgac acggccgtgt attattgtgt gagagacttg 300
ggagctacgg gaggggacta ctggggccag ggaaccctgg tcaccgtctc ctca 354
<210>2
<211>118
<212>PRT
<213> Artificial sequence
<400>2
Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 1015
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Gly Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Pro Lys Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Arg Asp Leu Gly Ala Thr Gly Gly Asp Tyr Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
<210>3
<211>8
<212>PRT
<213> Artificial sequence
<400>3
Gly Tyr Ile Phe Thr Gly Tyr Tyr
1 5
<210>4
<211>8
<212>PRT
<213> Artificial sequence
<400>4
Ile Asn Pro Lys Ser Gly Gly Thr
1 5
<210>5
<211>11
<212>PRT
<213> Artificial sequence
<400>5
Val Arg Asp Leu Gly Ala Thr Gly Gly Asp Tyr
1 5 10
<210>6
<211>990
<212>DNA
<213> Artificial sequence
<400>6
gcatccacca agggcccatc tgtcttcccc ctggccccat cctccaagag cacctctggc 60
ggcacagctg ccctgggctg cctggtgaag gactacttcc ctgagcctgt gacagtgtcc 120
tggaactctg gcgccctgac cagcggcgtg cacaccttcc ctgctgtgct ccagtcctct 180
ggcctgtact ccctgagcag cgtggtgaca gtgccatcca gcagcctggg cacccagacc 240
tacatctgca atgtgaacca caagcccagc aacaccaagg tggacaagcg ggtggagccc 300
aagtcctgtg acaagaccca cacctgcccc ccatgccccg cccctgagct gctgggcggc 360
ccatctgtct tcctgttccc ccccaagccc aaggacaccc tgatgatctc ccggaccccc 420
gaggtgacct gtgtggtggt ggatgtgagc catgaggacc ccgaggtgaa gttcaactgg 480
tatgtggatg gcgtggaggt gcacaacgcc aagaccaagc cccgggagga gcagtacaac 540
agcacctacc gggtggtgag cgtgctgaca gtgctgcatc aggactggct gaatggcaag 600
gagtacaagt gcaaggtgtc caacaaggcc ctgcctgccc ccattgagaa gaccatctcc 660
aaggccaagg gccagccccg ggagccccag gtctacaccc tgcccccctc ccgggaggag 720
atgaccaaga accaggtgag cctgacctgc ctggtgaagg gcttctaccc cagcgacatt 780
gctgtggagt gggagagcaa cggccagcct gagaacaact acaagaccac cccccctgtg 840
ctggactctg atggctcctt cttcctgtac agcaagctga cagtggacaa gagccggtgg 900
cagcagggca atgtcttctc ctgctctgtg atgcatgagg ccctgcacaa ccactacacc 960
cagaagagcc tgtccctgtc ccccggcaag 990
<210>7
<211>330
<212>PRT
<213> Artificial sequence
<400>7
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210>8
<211>321
<212>DNA
<213> Artificial sequence
<400>8
gagctcgtgc tgactcagcc accttcagtg tcagtgtccc caggacaaac ggccagggtc 60
acctgctctg gagatgcatt gcccaaaaaa tatgcttatt ggtaccaaca gaagtcaggc 120
caggccccta tactggtcat ctatggggac aacaaacgac cctccgggat ccctgagaga 180
ttctctggct ccagctcagg gacaatggcc acgttgacca tcagtggggc ccaggtggag 240
gatgaagccg actactactg ttactcaata gacaggagtg gtaatcgggt attcggcgga 300
gggaccaggc tgaccgtcct a 321
<210>9
<211>107
<212>PRT
<213> Artificial sequence
<400>9
Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln
1 5 10 15
Thr Ala Arg Val Thr Cys Ser Gly Asp Ala Leu Pro Lys Lys Tyr Ala
20 25 30
Tyr Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Ile Leu Val Ile Tyr
35 40 45
Gly Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Ser Ser Gly Thr Met Ala Thr Leu Thr Ile Ser Gly Ala Gln Val Glu
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Ile Asp Arg Ser Gly Asn Arg
85 90 95
Val Phe Gly Gly Gly Thr Arg Leu Thr Val Leu
100 105
<210>10
<211>6
<212>PRT
<213> Artificial sequence
<400>10
Ala Leu Pro Lys Lys Tyr
1 5
<210>11
<211>3
<212>PRT
<213> Artificial sequence
<400>11
Gly Asp Asn
1
<210>12
<211>10
<212>PRT
<213> Artificial sequence
<400>12
Tyr Ser Ile Asp Arg Ser Gly Asn Arg Val
1 5 10
<210>13
<211>315
<212>DNA
<213> Artificial sequence
<400>13
cagcccaagg ccaaccccac cgtgaccctg ttccccccat cttctgagga gctgcaagcc 60
aacaaggcca ccctggtgtg cctgatctct gacttctacc ctggcgctgt gacagtggcc 120
tggaaggctg atggctctcc tgtgaaggct ggcgtggaga ccaccaagcc atctaagcag 180
tctaacaaca agtatgctgc ctcttcttac ctgtctctga cccctgagca gtggaagagc 240
caccggtctt actcttgcca ggtgacccat gagggctcta cagtggagaa gacagtggcc 300
cccacagagt gctct 315
<210>14
<211>105
<212>PRT
<213> Artificial sequence
<400>14
Gln Pro Lys Ala Asn Pro Thr Val Thr Leu Phe Pro Pro Ser Ser Glu
1 5 10 15
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
20 25 30
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val
35 40 45
Lys Ala Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys
50 55 60
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
65 70 75 80
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
85 90 95
Lys Thr Val Ala Pro Thr Glu Cys Ser
100 105
<210>15
<211>36
<212>DNA
<213> Artificial sequence
<400>15
ggtgtccact cgctacaggt gcagctggtg cagtct 36
<210>16
<211>30
<212>DNA
<213> Artificial sequence
<400>16
gcccttggtg gatgctgagg agacggtgac 30
<210>17
<211>39
<212>DNA
<213> Artificial sequence
<400>17
acagacgctc gctgctccta tgagctgact cagccacct 39
<210>18
<211>30
<212>DNA
<213> Artificial sequence
<400>18
gttggccttg ggctgtagga cggtcagcct 30
Claims (1)
1. The application of human anti-sialic acid combined immunoglobulin-like lectin-9 antibody IgG in preparing a medicament for inhibiting neutrophils is disclosed, wherein the amino acid sequence of a heavy chain variable region of the antibody is shown as SEQ ID No. 2; the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 9; the amino acid sequence of the heavy chain constant region is shown as SEQ ID NO. 7; the amino acid sequence of the light chain constant region is shown in SEQ ID NO. 14.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510870684.5A CN105367658B (en) | 2015-12-02 | 2015-12-02 | Human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510870684.5A CN105367658B (en) | 2015-12-02 | 2015-12-02 | Human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105367658A CN105367658A (en) | 2016-03-02 |
| CN105367658B true CN105367658B (en) | 2020-06-16 |
Family
ID=55370336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510870684.5A Active CN105367658B (en) | 2015-12-02 | 2015-12-02 | Human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105367658B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831989A (en) * | 2017-01-04 | 2017-06-13 | 中国人民解放军南京军区军事医学研究所 | The IgG antibody of the anti-sialic acid binding domain-immunoglobulin sample agglutinin 7 in people source and its application |
| US12103969B2 (en) * | 2018-09-25 | 2024-10-01 | Academia Sinica | Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371916A (en) * | 2001-02-28 | 2002-10-02 | 第二军医大学免疫学研究所 | Human siali acid conjugated immunoglobulin-like agglutinant, its coding sequence and use |
| CN101035807A (en) * | 2004-06-09 | 2007-09-12 | 泰勒公司 | Diagnosis and treatment of SIGLEC-6 associated diseases |
| CN102803293A (en) * | 2009-10-06 | 2012-11-28 | 阿莱斯亚生物疗法股份有限公司 | SIGLEC 15 antibodies in treating bone loss-related disease |
-
2015
- 2015-12-02 CN CN201510870684.5A patent/CN105367658B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371916A (en) * | 2001-02-28 | 2002-10-02 | 第二军医大学免疫学研究所 | Human siali acid conjugated immunoglobulin-like agglutinant, its coding sequence and use |
| CN101035807A (en) * | 2004-06-09 | 2007-09-12 | 泰勒公司 | Diagnosis and treatment of SIGLEC-6 associated diseases |
| CN102803293A (en) * | 2009-10-06 | 2012-11-28 | 阿莱斯亚生物疗法股份有限公司 | SIGLEC 15 antibodies in treating bone loss-related disease |
Non-Patent Citations (4)
| Title |
|---|
| Cloning, Characterization, and Phylogenetic Analysis of Siglec-9,a New Member of the CD33-related Group of Siglecs;Takashi Angata等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20000721;第275卷(第29期);第22127–22135页 * |
| Jiquan Q. Zhang等.Siglec-9, a Novel Sialic Acid Binding Member of the Immunoglobulin Superfamily Expressed Broadly on Human Blood Leukocytes.《THE JOURNAL OF BIOLOGICAL CHEMISTRY》.2000,第275卷(第29期), * |
| Siglec-9, a Novel Sialic Acid Binding Member of the Immunoglobulin Superfamily Expressed Broadly on Human Blood Leukocytes;Jiquan Q. Zhang等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20000508;第275卷(第29期);摘要，第22122页左栏最后1段至右栏第1段 * |
| Siglec-9V型结构域原核表达载体的构建、鉴定和初步表达;俞杨等;《国际检验医学杂志》;20130215;第34卷(第3期);第272页右栏倒数第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105367658A (en) | 2016-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102564097B1 (en) | Anti-GPC3 antibody | |
| CN107286242B (en) | The monoclonal antibody of anti-PD-1 | |
| CN102482355B (en) | Antibodies | |
| CN106939050B (en) | anti-PD 1 and CD19 bispecific antibodies and uses thereof | |
| CN111378043B (en) | Human-mouse chimeric anti-Siglec-15 whole-molecule IgG with neutralization function and preparation method and application thereof | |
| CN106892980B (en) | anti-VEGFR 2 monoclonal antibody and application thereof | |
| KR20160002713A (en) | Highly galactosylated anti-tnf-alpha antibodies and uses thereof | |
| CN110655582A (en) | Bispecific antibodies or antibody mixtures with a common light chain | |
| CN111560070A (en) | Antibody aiming at novel coronavirus NP protein and detection application thereof | |
| CN104114577A (en) | Antibodies against TL1a and uses thereof | |
| CN107043425B (en) | anti-PD 1 and CD20 bispecific antibodies and uses thereof | |
| CN113150151B (en) | C5aR antibody and preparation method and application thereof | |
| US20210122818A1 (en) | Humanized anti-bag3 antibodies | |
| CN106831989A (en) | The IgG antibody of the anti-sialic acid binding domain-immunoglobulin sample agglutinin 7 in people source and its application | |
| CN115386006A (en) | anti-GPRC 5D antibody, preparation method and application thereof | |
| CN105367658B (en) | Human anti-sialic acid binding immunoglobulin-like lectin-9 antibody IgG and application thereof | |
| CN110475788A (en) | Anti- CEACAM1 antibody and its application | |
| CN113683697B (en) | anti-B7-H3 antibody, preparation method and application thereof | |
| CN115386007A (en) | anti-GPRC 5D antibody, preparation method and application thereof | |
| CN105504062B (en) | The detection antibody of anti-CD 6 monoclonal antibody T1h a kind of and application | |
| CN109021105B (en) | Human anti-sialic acid binding immunoglobulin-like lectin-7/9 antibody IgG and application thereof | |
| CN107964045A (en) | A kind of full molecule IgG of people mouse inosculating antibody CXCR2 and its application | |
| CN113896793A (en) | Anti-human IL-17RC monoclonal antibody and application thereof | |
| CN112079928B (en) | anti-PD-L1 monoclonal antibody | |
| CN116199779B (en) | anti-LILRB 4 monoclonal antibody, antigen binding fragment thereof and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170313 Address after: 210016 Nanjing Xuanwu District, Jiangsu, the Imperial Palace Road, No. 2 Applicant after: Zhu Jin Applicant after: Zhou Linfu Address before: 210016 Nanjing Xuanwu District, Jiangsu, the Imperial Palace Road, No. 2 Applicant before: Zhu Jin |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |